克罗恩病与溃疡性结肠炎患者皮下英夫利西单抗CT-P13的群体药代动力学
该研究基于一项I期研究数据,建立皮下英夫利西单抗生物类似药CT-P13在克罗恩病和溃疡性结肠炎患者中的群体药代动力学模型。典型70kg、白蛋白44g/L患者半衰期为10.8天,清除率0.355L/d,生物利用度79.1%。体重、抗药抗体和白蛋白是清除率的临床相关协变量;模拟显示50或70kg患者皮下与静脉暴露相当,120kg患者皮下暴露较低。
要点
- 皮下CT-P13典型半衰期为10.8天,生物利用度79.1%,支持固定维持剂量。
- 体重增加、抗药抗体阳性及低白蛋白血症可增加CT-P13清除率。
- 120kg患者皮下给药的模拟累积暴露低于静脉给药,50或70kg患者两种途径暴露相当。
核心结论
- 该皮下CT-P13群体药代动力学模型支持固定皮下维持剂量,但重体重患者累积药物暴露较低。
研究设计与样本
- 基于两部分I期研究数据,包含静脉5mg/kg及可变维持皮下给药并频繁采血,对象为克罗恩病或溃疡性结肠炎患者,采用非线性混合效应模型进行群体药代动力学分析。
主要发现
- CT-P13药代动力学由二室模型描述,线性消除。
- 典型70kg、血清白蛋白44g/L患者半衰期为10.8天。
- 清除率典型值为0.355L/d,吸收常数0.273/d,生物利用度79.1%,中央分布容积3.10L,外周分布容积1.93L。
- 影响清除率的临床相关协变量包括体重(70至120kg增加43.2%)、抗药抗体存在(增加39%)和血清白蛋白浓度(44至32g/L增加30.1%)。
- 模拟显示50或70kg患者皮下与静脉给药暴露相当,120kg患者皮下给药暴露较低。
临床怎么用
- 皮下CT-P13可按固定维持剂量给药,但重体重患者需关注暴露可能偏低。
- 临床可关注体重、抗药抗体状态和血清白蛋白水平对CT-P13清除的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infliximab is a chimeric monoclonal antibody against tumour necrosis factor-alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT-P13, an infliximab biosimilar, was approved for clinical use. AIMS: To characterise CT-P13 pharmacokinetics (PK) and its clinically relevant determinants after subcutaneous administration through population PK modelling. METHODS: Data from a two-part Phase I study with intravenous (5 mg/kg) and variable maintenance subcutaneous dosing of CT-P13 with frequent PK sampling in patients with CD or UC were used. Population PK analysis was conducted by non-linear mixed effects modelling. Covariates affecting PK parameters were chosen based on their clinical relevance (effect size of ≥20%) using a full fixed-effect modelling approach. RESULTS: CT-P13 PK was described by a two-compartment model with linear elimination. The half-life in a typical 70 kg patient with serum albumin of 44 g/L was 10.8 days. The typical value for clearance was 0.355 L/d, absorption constant 0.273/d, bioavailability 79.1%, central volume of distribution 3.10 L and peripheral volume of distribution 1.93 L. Clinically relevant covariates affecting clearance were body weight (+43.2% from 70 to 120 kg), the presence of anti-drug antibodies (+39%) and serum albumin concentration (+30.1% from 44 to 32 g/L). Simulated drug exposure was comparable between routes of administration for patients weighing 50 or 70 kg, but lower with subcutaneous dosing in patients weighing 120 kg. CONCLUSIONS: This first population PK model for subcutaneous CT-P13 supports fixed subcutaneous maintenance dosing, although heavy patients had lower cumulative drug exposure.
引用
- Hanzel J, Bukkems LH, Gecse KB, et al. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2021. PMID: 34559426. doi:10.1111/apt.16609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。